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ABSTRACT
Natural killer (NK) cells mediate the acute rejection of bone marrow cell (BMC) allografts, but not solid tissue
grafts, in lethally irradiated mice. However, the mechanisms underlying this capability for rejecting BMC
remain unclear. NK cells express (1) inhibitory receptors specific for major histocompatibility complex (MHC)
class I molecules and (2) activating receptors with diverse specificities. Inhibitory NK receptors confer to NK
cells the ability to discriminate between MHC class I–positive and –negative target cells and are therefore
involved in the control of NK cell tolerance to self, as well as in the elimination of cells that have downregu-
lation of MHC class I molecules. Preclinical studies in mice have provided good evidence that subsets of NK
cells that bear different combinations of both inhibitory and activating Ly49 receptors can interact with each
other and target specific BMC rejection, as well as NK cell responses toward tumor cells. Recent clinical
studies have also shown that the use of killer cell immunoglobulin–like receptor ligand incompatibility in
patients with leukemia who received hematopoietic stem cell transplants correlated not only with the elimi-
nation of graft rejection, but also with eradication of tumor and prevention of graft-versus-host disease; this
offers a significant advantage for survival. In this review, we attempt to bring together literature regarding the
biology of NK cells and discuss the current issues in bone marrow transplantation and the potential clinical role
of NK cell alloreactivity in the efficacy of this procedure for immunotherapy of cancer and infectious states.
© 2003 American Society for Blood and Marrow Transplantation
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Natural killer (NK) cells were initially described in
erms of function in 1971 by the observation of Cud-
owicz and Bennett [1,2] that lethally irradiated mice
ere capable of rejecting allogeneic or parental strain
one marrow cell (BMC) allografts. They observed
hat irradiated F1 hybrid H-2–heterozygous mice
AB) were capable of rejecting parental H-2–ho-
ozygous BMC (A or B). This observation conﬂicted
ith the classic laws of transplantation in which trans-
lantation antigens were thought to inherit co-domi-
antly (ie, parental antigens expressed by the F1 hy-
rid) and offspring were obligately tolerant toward h
B&MTarental major histocompatibility complex (MHC)
eterminants [2]. They termed this phenomenon hy-
rid resistance (Figure 1). The cells responsible for this
henomenon were found to be radioresistant and
dentical to lymphoid cells, which were characterized
ater in 1975 by their ability to mediate spontaneous
illing of tumors in vitro in an MHC-unrestricted
anner [3-6]. The term natural killer was given to
hese effector cells. Additional evidence that NK cells
lone could mediate the speciﬁcity of marrow graft
ejection emerged in 1987 when it was observed that
ice with severe combined immune deﬁciency
SCID), which cannot develop T and B cells because
f a failure in T- and B-cell receptor rearrangements,Alloreactivity
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ave normal NK cell function [7]. Despite intensive
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investigation by many laboratories, why and how NK
cells mediate BMC rejection still remain unclear.
NK CELL BIOLOGY
NK cells are lymphoid cells that reside in the
peripheral blood, spleen, bone marrow (BM), and
other tissues; represent an important arm of innate
immunity; and are thought to play a critical role in the
immune surveillance against tumors and virally in-
fected cells. NK cells in both mice and humans are
phenotypically characterized by both positive and
negative criteria because of the absence of truly NK-
speciﬁc and restricted markers. Markers thought to be
NK speciﬁc (NK1.1, DX5, and asialo GM1 in the
mouse and CD56 and CD16 in humans) are also
present on certain T-cell subsets or other cell types.
Therefore, NK cells can be deﬁned as cells that ex-
press these markers but are also negative for T-cell
markers such as CD3 and CD4 and do not rearrange
receptors such as T-cell receptors or immunoglobulin
for antigen recognition [4,5]. NK cells seem to medi-
ate cytotoxicity primarily through the perforin/gran-
zyme-dependent pathway, even though they also can
use Fas ligand and tumor necrosis factor (TNF)–re-
lated apoptosis-inducing ligand (TRAIL) to kill target
cells [8]. NK cells also mediate their function through
the secretion of a wide range of cytokines, particularly
on activation [9], that can both promote (granulocyte-
monocyte colony-stimulating factor [GM-CSF] and
granulocyte cell-stimulating factor [GCSF]) and in-
hibit interferon (IFN)– and transforming growth fac-
tor (TGF)– hematopoiesis [9-11]. NK-cell differ-
entiation and activity also seem to be affected by
several key cytokines. Interleukin (IL)–2, IL-15, and
IL-21, cytokines that share the  chain of the IL-2
receptor, are capable of inducing proliferation and
activation of NK cells, but only IL-15 has been shown
to play a crucial role in NK-cell development [12-16].
Indeed, in contrast to IL-2–deﬁcient mice, IL-15
knockout mice lack functional mature NK cells
[15,16]. In contrast to T cells that require the thymus
for differentiation, NK cell development is critically
dependent on the BM [12,13,17]. However, it has
been shown that common NK- and T-cell progenitors
can exist within the thymus, thus demonstrating the
close association of these 2 cell types [18]. Stem cell
factor (SCF) and fetal liver kinase ligands (ﬂk2L/ﬂt3L)
have been demonstrated to be critical in early NK-cell
differentiation [19]. Stromal cells are also thought to
be important in NK cell differentiation [20]. IL-12
and IFN- exert potent stimulatory effects on NK
cells, and the combination of IL-12 and IL-18 is
particularly effective in augmenting NK cell function
[4,21]. In humans, adoptive immunotherapy with IL-
2–activated NK cells after autologous bone marrow
transplantation (BMT) has been used with acceptable
toxicities in patients with cancer [22]. The ability to
manipulate NK-cell development and increase NK-
cell activity by using other cytokines (ie, IL-15 and
IL-21) may open new avenues in therapy of malig-
nancy.
NK CELL INHIBITORY AND ACTIVATING RECEPTORS
The “missing-self ” hypothesis proposed by Ljung-
gren and Karre [23] in 1985 is based on the observa-
tion that tumor cells that lack MHC class I molecules
are susceptible to killing by NK cells. These investi-
gators observed that variants of certain murine leuke-
mia cell lines that had lost expression of H-2 mole-
cules on the cell surface were more susceptible to lysis
by NK cells than the H-2–bearing leukemia cells [24].
Additionally, Storkus et al. [25] noted that human NK
cells lyse class I–deﬁcient Epstein-Barr virus–trans-
formed B-lymphoblastoid cell lines. It is interesting to
note that the transfection of murine H-2–deﬁcient
leukemia cells or human HLA class I–deﬁcient B-
lymphoblastoid cells with H-27 or HLA class I genes,
respectively, caused these target cells to be partially or
Figure 1. BMC and solid-organ rejection was originally observed in
mice. After lethal irradiation, mice remained capable of resisting
allogeneic (A into B) BMC and solid organ grafts, as reﬂected by
low engraftment rates. In addition, (AB) F1 hybrid mice were
capable of resisting parental BMC grafts in what was termed hybrid
resistance but were able to accept solid-organ grafts. It is interesting
to note that BMC grafts from F1 hybrid mice were only weakly
resisted by parental mice, and solid-organ grafts were totally re-
sisted by parental mice.
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completely resistant to NK cell–mediated lysis
[25,26]. However, MHC class I is not always necessary
for protection from NK-cell mediated cytotoxicity,
and recognition by MHC class I does not always
prevent cytolysis by NK cells. Indeed, NK cells are
unable to reject MHC class I–deﬁcient nonhemato-
poietic tissues (ie, skin grafts) and fail in vitro to lyse
cells that lack MHC class I molecules from 2-micro-
globulin null mice [27]. Alternatively, autologous NK
cells are able to kill someMHC-bearing virus-infected
cells [28], and, when activated with IL-2, these effec-
tors kill NK cell–resistant targets [29]. Over the past
decade, the identiﬁcation of diverse MHC class I–
speciﬁc inhibitory and activating receptors and non–
MHC class I–speciﬁc activating receptors (Figure 2a
and b) has revealed the complexity of the innate rec-
ognition of foreign or abnormal cells by NK cells and
has become relevant with respect to allogeneic BMT
and cancer therapy.
The ﬁrst family of MHC class I–speciﬁc receptors,
Ly49, was identiﬁed in the mouse. These receptors are
type II integral membrane homodimers, lectin-related
molecules, that recognize the MHC class Ia molecules
H-2D, H-2K, or both [30-32]. The second family
comprises the killer cell immunoglobulin–like recep-
tors (KIR). These type I transmembrane molecules,
which belong to the immunoglobulin superfamily, are
expressed in humans and are structurally characterized
by 2 or 3 extracellular immunoglobulin-like domains
that speciﬁcally recognize groups of HLA-C (p58 or
KIR2DL1–KIR2DL3) [33-36], HLA-B (p70 or
KIR3DL1) [37-40], and HLA-A (p140) alleles [41,42].
In contrast to Ly49 molecules, KIRs display more
complexity and different specialization [43]. Both the
Ly49 and the KIR multireceptor families comprise
receptors with inhibitory or activating action. The
inhibitory forms mediate their action via immunore-
ceptor tyrosine-based inhibition motifs (ITIMs)
[44,45] on binding the appropriate MHC determi-
nant. The ITIM tyrosines are then phosphorylated
and attract tyrosine phosphatase-1, which inhibits ac-
tivating signals. The activating versions have trun-
cated cytoplasmic domains that lack ITIMs. These
receptors associate with the immunoreceptor ty-
rosine-based activation motif (ITAM)–bearing
adapter molecule DAP12 via a charged residue in the
transmembrane region, which results in an activating
signal [46,47]. The ﬁrst close rodent homolog of the
NK receptor KIR family, the KIR-like–1 (KIRL1),
was recently discovered [48]. KIRL1 shares 40%
amino acid identity with primate KIR family mem-
bers, and most of the homology is contained within
the immunoglobulin-like ectodomains. It is interest-
ing to note that KIRL1 lacks the ITIM and ITAM
motifs found in the diverse KIRs. KIRL1 is broadly
expressed at low levels, including in IL-2–expanded
NK cells, but is highly expressed in immature thymo-
cytes. The exact function of this receptor is still un-
known.
The third family of MHC class I–speciﬁc recep-
tors expressed by both mice and humans is composed
of the C-type lectin molecule, CD94, which is co-
valently associated with a member of the NKG2 fam-
ily. These have also been shown to exert inhibitory
(NKG2A or B) or activating (NKG2C) signals on
binding Qa-1b (mouse) or nonclassic HLA-E (human)
molecules on targets [49-52]. CD94/NKG2 receptors
display less well deﬁned allele speciﬁcity than KIR
receptors [53].
Recently, a novel lectin-like receptor, KLRE1,
that inhibits NK cell cytotoxicity was identiﬁed in
both mice and rats [54]. This type II transmembrane
receptor seems to form a functional heterodimer with
an as-yet unidentiﬁed ITIM-bearing partner that re-
cruits SHP-1 to generate an inhibitory receptor com-
plex. The nonclassic (class Ib) HLA-G molecule, pri-
marily expressed on fetal cells of the human placenta,
interacts with other type of receptors expressed on
maternal decidual NK cells, the immunoglobulin-like
transcript (ILT) receptors, and seems to protect the
fetus and placenta from rejection [55].
In any given mouse or individual, an NK cell
subset can usually express 2 to 4 of the Ly49 or KIR
receptors characterized. The receptors have different
afﬁnities for the different MHC molecules (ie,
Ly49C/I has a strong afﬁnity for H-2Kb but can also
bind H-2Kd to a lesser extent) [56,57]. It also seems
that some of the receptors have the same binding
speciﬁcity with regard to MHC molecules (ie, Ly49A
and Ly49G2 both recognize H-2Dd). A single KIR
can recognize determinants that are shared between
members of a group of HLA alleles [58]. For example,
the inhibitory receptors KIR2DL2 and KIR2DL3 and
the activating receptors KIR2DS2 and KIR2DS3 rec-
ognize group 1 HLA-C alleles (Cw1, Cw3, Cw7, and
Cw8). The inhibitory KIR2DL1 and activating
KIR2DS1 recognize the group 2 HLA-C alleles (w2,
w4, w5, and w6). HLA-C is the predominant class I
isotype involved in the inhibitory and activating reg-
ulation of human NK cells.
The biologic signiﬁcance of the existence of paired
inhibitory and activating receptors for MHC class I
molecules remains unclear. It may play a central role
in the regulation of NK-cell function. In the case of
both KIRs and CD94/NKG2 receptors, the inhibitory
forms have greater afﬁnity for the corresponding
group of HLA alleles than do the activating forms
[59,60]; this causes NK cells that express both forms of
receptors to be inhibited from killing. Thus, activating
receptors speciﬁc for MHC class I molecules may
signal only when target cells have lost the expression
of an HLA molecule recognized by the inhibitory
receptor, therefore allowing the activating receptor to
engage its ligand. In this way, NK cells have the ability
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Figure 2. NK cells express multiple inhibitory and activating cell-surface receptors that belong to the immunoglobulin superfamily (KIR),
C-like lectin family (CD94), NKG2 A, B, and C, and immunoglobulin-like molecule family (NKps and NKG2D). Some receptors bind either
classic (HLA-A, -B, and -C) or nonclassic (HLA-E and -G) MHC class I ligands or have binding speciﬁcity for non–MHC class I molecules
(immunoglobulin G, MICA/B, and ULBPs). a, Inhibitory receptors are distinguished by ITIM domains in their cytoplasmic tails, which on
activation attract tyrosine phosphatase-1 phosphatases and send a potent inhibitory signal to the nucleus of NK cells, preventing them from
killing certain targets. b, Activating receptors initiate cytokine production and NK-cell cytotoxicity. These receptors have short cytoplasmic
domains but are associated with adapter proteins, such as DAP12, DAP10, and FcR. On binding to ligand, the adapter molecules send
activating signals to the NK-cell nucleus via their intracytoplasmic ITAM tails. The ligands for NKps receptors are unknown but are not likely
to be MHC molecules. NK cells also express the activating Fc receptor CD16 for immunoglobulin. Mouse NK cells express similar
MHC-binding receptors, termed Ly49 molecules.
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to recognize and be triggered to kill cells that have
downregulated or lost a certain MHC class I mole-
cule, whereas normal cells are left unaffected [61].
Given the fact that the expression of both Ly49 and
KIR on NK cells and MHC molecules on target cells
can be modulated, this receptor/ligand system, which
lacks the diversiﬁcation power of gene recombination,
gives the NK cell the ability to recognize and react to
numerous potential target cells.
Other activating NK-cell receptors are repre-
sented by a heterogeneous family of NK cell–speciﬁc
immunoglobulin-like molecules that are known as
natural cytotoxicity receptors (NCRs; these include
NKp30, NKp46, and NKp44) and by NKG2D, a
member of the NKG2 family that is expressed by NK
cells and cytotoxic T lymphocytes [62-65]. In contrast
to activating KIRs and CD94/NKG2C receptors,
NCRs and NKG2D mediate cytotoxicity against
MHC class I–deﬁcient or negative targets. The cel-
lular ligands for NCRs remain to be identiﬁed,
whereas those for NKG2D include the MHC class
I–related gene A and B (MICA andMICB) and UL16-
binding proteins (ULBP) in humans [64,65] and
Rae-1 or retinoic acid and H-60 in mice [66]. NKp46
and NKp30 are constitutively expressed by all periph-
eral blood NK cells [67,68]. NKp44 is expressed by
IL-2–activated NK cells [69]. These receptors signal
through coupling with DAP12 or ITAM-containing
CD3 and/or FcRI adapter proteins and are in-
volved in the recognition and killing of various tumor
cells. NKG2D is expressed as a homodimer, along
with the adapter molecule DAP10, to form a receptor
similar to activating Ly49 receptors [49]. NKG2D
seems to mediate the killing of cells that have been
altered by stress or neoplastic transformation. This
complex system of innate recognition of target cells by
NK cells may be the most powerful tool for clinical
application in allogeneic BMT and cancer treatment.
Additionally, most NK cells express the FcRIII
CD16, which, on binding to the Fc component of the
immunoglobulin molecule, activates antibody-depen-
dent cellular cytotoxicity [70], giving the NK cells
multiple means for target recognition.
ROLE OF NK CELLS AND RESPECTIVE SUBSETS IN
GRAFT REJECTION
BMT has become an accepted method of therapy
for the treatment of various hematologic malignan-
cies. Usually, this procedure includes a conditioning
regimen that involves irradiation or chemotherapy.
These regimens can be either myeloablative or of
reduced intensity, also calledminitransplantations (con-
sisting of less cytoreductive conditioning but involving
more extensive use of host immunosuppression, such
as steroids and cyclosporin A). The sources of hema-
topoietic stem cells to repopulate the individual are
either autologous (hematopoietic stem cells isolated
from the recipient) or allogeneic (involving related or
unrelated HLA-matched donors or donors with vary-
ing degrees of HLA mismatch). The efﬁcacy of allo-
geneic BMT is limited by several obstacles, such as
rejection of the graft, the occurrence of graft-versus-
host disease (GVHD), relapse of the original tumor,
and susceptibility of patients to opportunistic infec-
tions because of the immunosuppressive effects of the
conditioning regimen.
There is ample evidence that NK cells are a bar-
rier to the engraftment of BM allografts and that they
alone can mediate the speciﬁcity of BMC rejection in
mice [7,71-74]. It was observed that SCID mice that
lacked T and B cells but had normal NK-cell function
were able to reject BMC allografts, but not solid tissue
allografts, even after lethal irradiation [7]. In humans,
however, the evidence has been less deﬁnitive. Clini-
cally, the allograft resistance observed in patients with
SCID who have received HLA-mismatched BMTs
depleted of T cells, without cytoreductive condition-
ing, is attributed to high activity of NK cells from the
donor [75]. Recent clinical studies have shown that the
presence of certain HLA-C alleles correlates with an
increased risk for BM allograft rejection [76].
One of the difﬁculties in assessing NK cells and
BMC rejection is that at present, there is no in vitro
assay that adequately reﬂects in vivo BMC rejection in
mice. The in vivo assays to assess BMC engraftment
have remained unchanged for many years. These in-
clude the splenic hematopoietic colony-forming unit
cell (CFU-C) assay and the splenic incorporation of
iodine 125–iododeoxyuridine (125IUdR) assay (Figure
3). These short-term studies need to be correlated
with determination of long-term chimerism to ascer-
tain whether resistance to the donor BMC graft is
indeed occurring. Numerous variables need to be con-
sidered in the process of BM allograft rejection. In
humans, it is difﬁcult to discern T-cell–mediated from
NK-cell–mediated resistance because both cell types
have many of the same surface markers. Because of the
extreme toxicities associated with conventional BMT
procedures, nonmyeloablative transplantation regi-
mens are being increasingly used [77]. Although these
regimens involve less conditioning, to reduce toxici-
ties, the increased presence of host NK cells may
increase the rejection, and experimental data suggest
that this can indeed result [78]. It is relatively easy to
override NK cell–mediated rejection by increasing the
BMC number after lethal total body irradiation [17].
Moreover, it has been noted that particular genes of
the NK gene complex on chromosome 6 have the
ability to regulate BM rejection in certain strains of
mouse [79], suggesting that the correlation with clin-
ical resistance may involve various variables. It is im-
portant to note that BMC rejection ability has been
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shown to depend on the status of the mouse colony
where the animals are housed. Perforin-deﬁcient mice
and Fas ligand mutant mice were found to be incapa-
ble of rejecting BMC allografts at one institution yet
were capable of rejecting the same BMCs at another
institution [80]. This suggests that other factors (ie,
subclinical infections) present in the different mouse
colonies may alter NK cell function and dependence
on certain cytotoxic pathways. Additionally, the pre-
cise target in the BMCs that NK cells attack (ie, the
stem cell, committed progenitors, and stromal ele-
ments) is not known. All these variables make it difﬁ-
cult, not only to discern the mechanism of NK cell–
mediated BMC rejection, but also to extrapolate these
data to the clinical perspective.
NK cell subsets have been shown to play a pivotal
role in BMC rejection in mice [81-85]. In instances of
hybrid resistance, the NK cell subsets from (B6D2) F1
hybrid mice (H-2bxd) expressing only inhibitory re-
ceptors for either H-2Kb (ie, Ly49C/I) or H-2Kd (ie,
Ly49A or Ly49G2) are able to reject BMC from
either parent [81,82]. In speciﬁc strains of mice, NK
cell subsets expressing certain inhibitory or activating
Ly49 receptors seem to be responsible for the resis-
tance to allogeneic marrow, depending on the MHC
expression on the BMC (Table 1). The mechanism
underlying both allogeneic and hybrid resistance is at
least partially explained by MHC class I–speciﬁc in-
hibitory receptors that deliver inhibitory signals that
dominate the immune response (Figure 4). The pat-
tern of BM rejection seen in preclinical studies is
correlated with the in vitro speciﬁcity seen in cytotox-
Figure 3. In vivo model to assess BMC engraftment. Mice were given cytoreductive conditioning in the form of lethal total body irradiation
and were then intravenously infused with allogeneic BMCs. BMC engraftment was assessed through a splenic CFU-C assay or by measuring
the splenic incorporation of 125IUdR, which is a DNA precursor analog. The spleen is the primary organ to repopulate with hematopoietic
cells. For the CFU-C assay, a spleen suspension with a known amount of cells was plated in soft agar with exogenous cytokines (ie, IL-3 and
GM-CSF), and 7 to 10 days later, the extent of colony formation was determined. The 125IUdR assay involves injection of this radioisotope
in vivo, followed by the removal of the spleens 5 to 7 days after BMC transplantation and measurement of radioactivity in a gamma counter.
The 125IUdR assay is less speciﬁc for hematopoietic cells, because all rapidly proliferating cells will be detected. Donor cell chimerism was also
determined 40 days after transplantation.
Table I. Effects of In Vivo Depletion of NK Cells Subsets in the Rejection of BMC
Donor3Host
Effect of Depletion
Ly-49A Ly-49G2 Ly-49C/I Ly-49D Ly-49H
d3b ()* ()† ()† ()† ?
b3d ()* ()* ()‡  ?
b3k ()* ()*   ?
dxb3b     ?
dxb3d     ?
b3bxd ()* ()* ()‡  ?
d3bxd ()‡ ()‡   ?
*Synergistic effect if Ly-49A and Ly-49G2 depleted together.
†Additive effect if Ly-49C/I and Ly-49D depleted together.
‡Depletion results in greater rejection.
() Reﬂects extent of growth/engraftment; () represents rejection.
I. Barao and W. J. Murphy
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icity assays with mitogen-stimulated lymphoblast tar-
gets. For example, in F1 mice it was observed that
Ly49C/I NK cells mediated speciﬁc rejection of
H-2Dd BM allografts, whereas Ly49G2 NK cells
speciﬁcally rejected H-2Db BM allografts [82-85].
Curiously, even though this subset played no direct
role in mediating the rejection of BMC from this
haplotype, the depletion of the Ly49C/I NK subset
in vivo enhanced the ability of H-2d mice to reject
H-2b BMC (Table 1). This suggests that depletion of
the subset not mediating rejection is either enriching
the frequency of the subset that mediates rejection or
is removing an inhibitory effect of one NK cell subset
on the other. Additionally, it was found that different
NK cell subsets within a host could work together in
the rejection of BMC. Mice depleted of Ly49G2 or
Ly49ANK cells together, but not singly, were found
to be incapable of rejecting H-2Db, but not H-2Dd,
BM grafts in certain strains of mice. This suggests that
these 2 subsets work together in the rejection of BMC
(Table 1) [84]. It seems to be possible that Ly49
molecules are cross-reactive among H2 haplotypes.
Only a small subset of NK cells that express a non–
cross-reactive inhibitory receptor and do not coex-
press any Ly49 molecules that cross-react with the
allogeneic MHC are entirely responsible for rejection.
The ability of Ly49 receptors to receive inhibitory
signals through cross-reactivity with allogeneic MHC
class I molecules is biologically signiﬁcant, because
NK cells in normal mice are capable of rejecting
hematopoietic transplants from 2-microglobulin–de-
ﬁcient mice that lack normal cell-surface MHC class I
expression [86,87]. It remains unclear as to whether
activating receptors are required for BMC rejection or
whether merely the absence of inhibitory receptors
would be sufﬁcient to target this event. However, at
least with regard to H-2Dd BMC rejection by H-2Db
mice, up to 98% of NK cells expressing Ly49C/I
(which receive inhibitory signals by H-2Db) also ex-
press Ly49D (which receive activating signals from
H-2Dd [88]. Depletion of the activating receptor
Ly49D has been shown to abrogate the rejection of
H-2Dd BM in H-2Db mice, suggesting that this re-
ceptor transmits activating signals after interaction
with H-2Dd [83]. It is interesting to note that in those
studies depletion of both the activating Ly49D and
inhibitory Ly49C/I subsets from the host resulted in
even greater BMC engraftment of H-2d BMC allo-
grafts [85]. The study of BMC rejection in mice has
provided signiﬁcant information concerning the in
vivo functions of NK cells and their subsets, and this
has also led to the development of clinically testable
Figure 4. Potential role of NK-cell subsets in BMC rejection. Allogeneic BMC (in this case, H-2d BMC in H-2b recipients) can be resisted
by NK cells that do not have inhibitory Ly49 receptors (containing ITIM) for H-2Kd (ie, Ly49C/I subset) and have activating receptors
(associated with ITAM) for H-2Kd (ie, Ly49D subset). NK-cell subsets expressing inhibitory receptors for H-2Kd (ie, Ly49A or Ly49G2
subset) will become inactivated on interaction with the BMC, even in the presence of activating receptors. Possibly Ly49D NK cells are
activated to reject H-2d BMC through other yet-unknown activating receptors.
NK Cells and BM Allograft Rejection
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strategies for their clinical exploitation in cancer and
infectious disease. It has been recently shown that
Ly49H, an activating Ly49, plays a role in resistance
to lymphocytic choriomeningitis virus [89-91]; this
demonstrates other key roles of these subsets and
potential clinical uses for them. The role of this subset
in BMT rejection remains to be determined (Table 1).
NK CELL SUBSETS AND GVHD
The occurrence of GVHD after allogeneic BMT
is a signiﬁcant cause of morbidity, but it is also asso-
ciated with a beneﬁcial graft-versus-tumor (GVT) ef-
fect that signiﬁcantly decreases the relapse rate when
compared with autologous BMT. Donor T cells
present in the graft mediate GVT responses but are
also able to initiate GVHD after recognizing the host
as foreign (by both major and minor histocompatibil-
ity differences), and then they attack the host. The
donor T cells then expand, release inﬂammatory cy-
tokines, and recruit other cell types (ie, NK cells,
macrophages, and monocytes) to mediate tissue in-
jury. T-cell depletion is usually performed on the
allograft before transplantation to reduce the risk of
GVHD, but it also results in an increased risk of graft
rejection, delayed immune reconstitution, higher re-
lapse rates, and increased susceptibility to opportunis-
tic infections. Because NK cells do not directly induce
solid tissue destruction, these cells may be opportune
mediators of GVT without exacerbating GVHD.
The contribution of NK cells in the control of
tumor growth without causing GVHD is well estab-
lished in mice (Figure 5). Zeis et al. [92] were able to
induce antileukemia effects after BMT without induc-
ing GVHD by infusing allogeneic donor-derived IL-
2–activated NK cells in syngeneic mice bearing leu-
kemia. It is interesting to note that mice receiving
syngeneic NK cells had an inferior antileukemia effect
in comparison. Moreover, 85% of mice that under-
went transplantation with allogeneic BMT but with
no infusion of NK cells died from severe GVHD. It
was observed that adoptive transfer of activated NK
cells from H-2d mice into advanced metastatic solid
tumor–bearing H-2b mice after allogeneic BMT also
promoted signiﬁcant antitumor effects, prevented
GVHD, and increased mouse survival [93,94]. In this
study, the postadministration of donor T cells resulted
in signiﬁcant morbidity in the tumor-bearing mice
because of GVHD, whereas simultaneous infusions of
activated NK cells could inhibit GVHD and promote
GVT in these mice. GVHD suppression seemed to be
suppressed by the potent immunosuppressive cytokine
TGF-, because administration of neutralizing
TGF- antibodies eliminated the protective effect of
NK cells. This is also supported by observations that
activated NK cells could inhibit T-cell responses in
vitro, in part through the production of this cytokine
[94,95].
NK cell subsets bearing certain inhibitory recep-
tors have been shown to prevent GVHD to a much
greater extent than whole populations. In a study by
Ruggeri et al. [96], murine Ly49A/G2/Ly49C/I
and Ly49A/G2/Ly49C/I NK-cell subsets ob-
tained from splenocytes of H-2bxd mice were puriﬁed
and assayed for alloreactivity by using H-2b or H-2d
recipients as targets. This study revealed that donor
Ly49A/G2/Ly49C/I alloreactive NK-cell subsets
(the Ly49G2 receptor is speciﬁc for H-2d) were
activated to kill the recipient’s targets (H-2b) without
causing GVHD, even when large numbers of alloreac-
tive NK cells were infused into lethally irradiated
mice. Similar results were obtained when donor NK
cells expressing Ly49C/I receptors speciﬁc for H-2b
were administered to H-2d mice. They correlated this
protection with a reduction in host dendritic cells,
suggesting that this was the mechanism by which
donor NK cells prevented GVHD (Figure 5).
The timing of the NK-cell administration seems
to be critical in murine models. Preclinical studies
indicate that NK cells must be given early after BMT
before the ampliﬁcation of GVHD occurs. If the ad-
ministration of NK cells is delayed after the initiation
of GVHD by the donor T cells, the incidence and
severity of GVHD will increase. This is consistent
with the detection of NK cells in GVHD lesions and
with the ﬁnding that administration of cytokines such
as IL-2 and IL-12 can prevent GVHD when given
early but augment it when given late after BMT. Once
GVHD is active and ongoing, NK cells can aggravate
GVHD and participate in GVHD pathology, possibly
through the release of inﬂammatory cytokines. The
occurrence of GVHD can be efﬁciently minimized
through the depletion of donor T cells from the graft
before the transplantation. The ability of donor NK
cells given before the infusion of the BM graft to
prevent GVHD in either myeloablative or nonmy-
eloablative conditioning regimens still needs to be
examined in humans.
NK CELL SUBSETS AND GVT EFFECTS
Many of the clinical studies evaluating the efﬁcacy
of IL-2 administration after autologous BMT re-
ported that in some cases the increase in NK and
lymphokine-activated killer cell activity seemed to
correlate with antitumor effects [5,97-99]. Adoptive
transfer of IL-2–activated NK cells has been shown to
promote signiﬁcant GVT effects and suppress GVHD
after allogeneic BMT in advanced tumor–bearing
mice [94], with subsequent increases in survival. The
mechanisms by which NK cells exert their antitumor
effects could be by direct cytotoxicity with perforin/
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granzymes, FasL, or TRAIL or through the produc-
tion of inﬂammatory cytokines, such as TNF-,
IFN-, or both [8,9]. The characterization of diverse
MHC class I–speciﬁc receptors suggests that even
greater antitumor effects are possible with NK cells.
Approximately 50% of murine NK cells were found to
have Ly49 and CD94/NKG2A inhibitory receptors
[52,88]. Because the inhibitory signal delivered to the
NK on binding the appropriate MHC can prevent
stimulatory signals, blockade of this interaction may
augment NK-cell activity against the tumor. On the
basis of the knowledge obtained from the BMT de-
pletion studies, it is possible to determine what recep-
tors need to be blocked to improve antitumor re-
sponses. For example, Ly49C/I NK cells have been
demonstrated to bind and become inactivated by cells
expressing H-2Db [100]. These same subsets are in-
volved in the rejection of H-2d BMC. The blockade of
these receptors with F(ab	)2 fragments of monoclonal
antibodies increases the ability of syngeneic or alloge-
neic NK cells to kill tumor cells expressing this MHC
allele both in vitro and in vivo [101,102]. These same
Figure 5. NK cells can suppress GVHD and mediate allogeneic BMT and GVT effects through various pathways. Donor NK cells promote
donor BMC engraftment, presumably through the production of hematopoietic growth factors (ie, GM-CSF, granulocyte cell-stimulating
factor, IL-1, and IL-6). NK cells of donor type are also able to prevent GVH reactions. These effectors can suppress donor T cells through
production of the immunosuppressive cytokine TGF- or prevent T-cell priming by eliminating host dendritic cells. Increased donor
engraftment can also be achieved through the suppression of host effector cells (NK and T cells), thus preventing graft rejection. Finally, donor
NK cells can mediate GVT effects through direct cytotoxicity (perforin/granzymes, FasL, and tumor necrosis factor–related apoptosis-
inducing ligand), secretion of cytokines (TNF- and IFN-), or both.
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studies demonstrated that allogeneic NK cells (H-2
mismatched to the tumor) were much more effective
than syngeneic NK cells in tumor eradication. Similar
results have been obtained by using puriﬁed NK cell
subsets that do not receive inhibitory signals to the
MHC present on the tumor cells. It is important to
note that no adverse effects were detected in vivo by
the removal of inhibitory signals to self-MHC in mice
that received the NK cells [101]. These results suggest
that inhibitory receptor blockade or the use of NK cell
subsets can be of potential use to increase the antitu-
mor efﬁcacy of NK cells. Similarly, blocking CD94/
NKG2A in addition to Ly49 family members may
improve efﬁcacy. Additionally, it has been recently
shown in humans that KIR ligand incompatibility re-
sulted in signiﬁcantly lower relapse rates and reduced
graft rejection in patients with acute myeloid leukemia
(AML) who received mismatched allogeneic BMTs
[96]. All these observations therefore suggest that
adoptive transfer of NK cell subsets in a highly acti-
vated state (ie, stimulation with IL-2, IL-15, or both)
may be needed for optimal efﬁcacy.
NK CELL SUBSETS AND HEMATOPOIESIS
NK cells have been demonstrated to promote
hematopoiesis and, therefore, BM engraftment
[6,74,99,103,104]. Activated NK cells in mice produce
hematopoietically active cytokines such as GM-CSF,
granulocyte cell-stimulating factor, IL-1, and IL-6
and also growth-inhibitory cytokines including
IFN-, TNF-, and TGF- [9-11]. We observed that
depending on the in vitro assay conditions used, NK
cells can either promote or inhibit hematopoiesis.
When BMCs are placed under optimal growth con-
ditions with exogenous cytokines (ie, IL-3 and GM-
CSF), the addition of IL-2–activated NK cells is in-
hibitory for hematopoiesis growth, partly because of
the production of IFN-, TNF-, or both by these
effectors [11,105]. However, when BMCs are cultured
without exogenous cytokines, in which the BMC will
not survive, the addition of IL-2–activated NK cells
will promote hematopoietic growth [11]. In vivo,
adoptively transferred IL-2–activated donor NK cells
promoted hematopoietic reconstitution after synge-
neic and allogeneic BMT in mice, especially after T
cell–depleted transplantation [11,106]. However, all
these studies used whole NK-cell populations. The
various NK-cell subsets that have been described in
the context of target speciﬁcity toward tumor targets
also play a signiﬁcant role in the physiological regu-
lation of hematopoiesis and can potentially negate or
mask the effects of each other. In vivo depletion stud-
ies were performed to determine the role of Ly49C/I
NK cells on hematopoiesis in H-2d mice. We dem-
onstrated that this particular NK-cell subset pro-
moted hematopoietic growth in H-2d mice and inhib-
ited hematopoietic growth in H-2b mice, whereas the
Ly49C/I NK cells and whole NK-cell population
seemed to provide an inhibitory effect in H-2d hema-
topoietic growth [107]. Similarly, in H-2b mice, the
Ly49G2 NK cell subsets inhibited hematopoiesis
[108]. It is interesting to note that cytokine production
by the diverse NK-cell subsets seems to play a pivotal
role in the regulation of hematopoiesis; Ly49C/INK
cells produce more GM-CSF than IFN-, in contrast
to Ly49G2 NK cells [92]. Although additional stud-
ies still need to be performed to deﬁne the mecha-
nisms that underlie the effects of the diverse NK-cell
subsets on hematopoietic engraftment, these mecha-
nisms seem to be dependent on the expression of
certain MHC class I–recognizing receptors on NK
cells.
Figure 6. Regulation of NK-cell responses by inhibitory receptors. a, KIR ligand match in HLA-mismatched BMT—donor NK cells have
inhibitory receptors that recognize and bind MHC class I molecules on host tumor cells (ie, KIR2DL1:HLA-C w4), and inhibition of lysis
occurs. b, KIR ligand mismatch in HLA-mismatched BMT—inhibitory receptors on donor NK cells do not recognize MHC class I molecules
expressed on host tumor cells (ie, KIR2DL1:HLA-C w3), and lysis occurs. The activating receptor (AR) binds the corresponding activating
ligand (AL), and NK cell–mediated cytotoxicity is triggered. KIR mismatch exerts a potent GVT effect and graft alloreactivity.
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NK CELL ALLOREACTIVITY AS THERAPY FOR
LEUKEMIA: RELEVANT PRECLINICAL AND CLINICAL
STUDIES
The incidence and severity of GVHD or failure
of the graft can be reduced signiﬁcantly with
HLA genotypically matched transplants. However, a
matched-HLA genotypic-identical sibling donor can
be found for only a proportion of patients with ma-
lignancies potentially curable by BMT. For these pa-
tients, the curative options are either an autologous
transplant or a transplant from an HLA-matched re-
lated or unrelated donor.
NK cells, unlike T cells, are better killer cells in
the absence of MHC class I molecules on a target.
When the appropriate MHC class I ligands are
present, the corresponding KIRs on the NK cells are
engaged, and these cells are not activated to kill the
tumor cells (Figure 6). There is good indication that
donor NK cells that lack inhibitory KIRs for host
MHC class I molecules can mediate a beneﬁcial NK-
versus-tumor reaction and reduce the incidence of
graft rejection after HLA-haplomismatched BMT.
Recently, Ruggieri and colleagues [96,109] provided
direct evidence for the clinical potential of allogeneic
NK cells in the eradication of leukemia. The role of
NK-cell alloreactivity in human HLA haplotype-mis-
matched hematopoietic stem cell transplantation and,
speciﬁcally, the role of the 3 major NK speciﬁcities (ie,
HLA-C group 1, HLA-C group 2, and HLA-B w4
alleles) were studied in 92 patients with high-risk
acute leukemia. The KIR-mismatched patients exhib-
ited 100% engraftment and no acute GVHD. Graft
rejection occurred in 15.5% of matched patients and
acute GVHD in 13.7%, probably because of residual
T cells. It is interesting to note that no AML relapses
were observed in the mismatched group, whereas in
the matched group, 75% of AML patients relapsed.
Surprisingly, AML patients with KIR-mismatched do-
nors exhibited a survival rate after 5 years of 60%,
compared with only 5% for matched unrelated donor
transplants. In contrast, patients with acute lympho-
blastic leukemia displayed similar relapse rates in the 2
groups (85% in the KIR ligand–mismatched group
and 90% in the matched group). This resistance to
NK cells may be due to the absence of surface acti-
vating ligands, adhesion molecules on the malignant
cells, or both. It will be of interest to evaluate means
to augment NK-cell recovery or adoptive transfer of
NK cells to ascertain whether increased efﬁcacy or
effects in patients with acute lymphoblastic leukemia
can be observed. These data have been recently con-
ﬁrmed in an expanded study [110]. However, another
study did not observe these results [111], suggesting
that differences in conditioning and the graft may
affect NK recovery and function and, therefore, clin-
ical responses. In mismatched mouse transplants, the
administration of donor alloreactive NK cells also
permitted the use of less severe conditioning regimens
and was able to promote stable donor chimerism [86].
Moreover, the use of total body irradiation together
with alloreactive NK-cell infusions permitted the use
of lethal doses of allogeneic T cells for immune re-
constitution. This conﬁrmed earlier demonstrations
that donor NK cells could promote engraftment after
syngeneic or allogeneic BMT in mice [103,104,106].
The described preclinical and clinical studies imply
that NK cell alloreactivity seems to provide a powerful
implement for enhancing the efﬁcacy and safety of
allogeneic hematopoietic transplantation in the im-
munotherapy of cancer.
PERSPECTIVES
Over the last 10 years, the accumulation of knowl-
edge on NK-cell receptors has brought new under-
standing of the role of NK cells as potential immune
effectors in allogeneic adoptive immunotherapy of
cancer. Although it is now known that NK-cell re-
sponses are a result of competing signals mediated
through MHC class I–speciﬁc inhibitory receptors
and MHC- and non-MHC class I–recognizing acti-
vating receptors, several other aspects of NK biology
and the mechanisms of regulation of NK sensitivity or
resistance to allografts remain to be elucidated. Future
studies in NK cell therapies that focus on inhibitory
receptor blockade or on the selection of donor NK
cell subsets that lack inhibitory receptors for host or
tumor, alone or in combination with cytokines that
augment NK-cell function, may have more therapeu-
tic efﬁcacy. Recent clinical trials have been successful
in testing the use of haploidentical stem cell trans-
plants, allogeneic NK cells, and NK-cell lines in a
KIR-ligand incompatibility manner as a main therapy
for leukemia, and possibly this strategy can be apply to
patients with other malignancies. Additionally, the
depletion of all host NK cells and the infusion of
certain donor NK-cell subsets to patients before pre-
transplantation conditioning may facilitate engraft-
ment without increasing GVHD but with a decreased
need for immunosuppression.
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